Lethal graft-versus-host reaction to minor histocompatibility antigens is decreased by donor immunization against H-2 and varies as a function of the H-2 haplotype.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Motta.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A highly purified extract from bovine spleen (FA) possessing immunosuppressive capacity was studied. Its tissue specificity was analysed in vivo and in vitro and the main components of FA, the well-known nucleosides deoxycytidine, deoxyinosine and thymidine, were tested in vivo. It seems that the molecule responsible for the biological activity of FA is a new substance endowed with strong specific activity and that lymphoid tissue is highly sensitive to the inhibiting capacity of this purified fraction.
It is demonstrated that, under experimental conditions resembling those used for bone marrow grafting in man, disparity for minor histocompatibility antigens alone (i.e., antigens coded for by genes not included in the major histocompatibility complex) is in fact sufficient for the induction of severe lethal graft-versus-host disease in adult (DBA/2 X B10.D2)F1 recipients of normal B10.D2 myeloid and lymphoid cells.
We have examined alkaline phosphatase in five commercial sera employing three analyzers. Alkaline phosphatase in three samples is underestimated or overestimated according to the analyzers used. Therefore we have studied the isoenzymatic fractions employing the fractionation of alkaline phosphatase on celluloseacetate. Alkaline phosphatase isoenzymes have physical and biochemical marks different from human sera. In human sera on the contrary have not noticed any difference according to the analyser used.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.